Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Buntanetap in Parkinson's Disease
NCT07284784Phase 3Recruiting
- Sponsor
- Annovis Bio, Inc.
- Start
- Jan 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of buntanetap in Parkinson's disease (PD), sponsored by Annovis Bio, Inc.. Started Jan 2026; status: recruiting.
02
Drugs
buntanetap
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07284784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284784.